Pharmacotherapy for mental health problems in people with intellectual disability

Current Opinion in Psychiatry
Na Young Ji, Robert Findling

Abstract

Psychotropic medications are commonly prescribed to people with intellectual disability. We reviewed current evidence-based pharmacotherapy options and recent updates to guide clinicians in their medication management plans. Antipsychotics, particularly risperidone, appear to be effective in reducing problem behaviors in children with intellectual disability. Evidence in adults is inconclusive. Methylphenidate appears to be effective, and α-agonists appear promising in reducing attention-deficit hyperactivity disorder symptoms. Lithium might be effective in reducing aggression. Evidence is limited to support the use of antiepileptic drugs, anxiolytics, and naltrexone for management of problem behaviors. Antidepressants may be poorly tolerated and might not be effective in reducing repetitive/stereotypic behaviors.In recent trials, glutamatergic and GABAergic agents for fragile X syndrome, and acetylcholinesterase inhibitors for Down's syndrome, failed to show efficacy. Growth hormone treatment might improve cognition and behavior in Prader-Willi syndrome population. Results from oxytocin trials on social behaviors are inconclusive albeit promising. Melatonin appears to improve sleep. Most trials of dietary supplements did not s...Continue Reading

References

May 1, 1975·The British Journal of Psychiatry : the Journal of Mental Science·E P WorrallG J Naylor
May 1, 1992·Journal of the American Academy of Child and Adolescent Psychiatry·B L HandenA Gosling
Jul 11, 1992·Journal of the American Academy of Child and Adolescent Psychiatry·E H CookB L Leventhal
Mar 1, 1991·Journal of the American Academy of Child and Adolescent Psychiatry·B L HandenS McAuliffe
Mar 1, 1991·Journal of the American Academy of Child and Adolescent Psychiatry·M G AmanS N Merry
Jan 1, 1990·Archives of Disease in Childhood·M SelikowitzS Wright
Sep 1, 1989·Journal of the American Academy of Child and Adolescent Psychiatry·J B PaytonW J Helsel
Apr 1, 1986·Journal of Clinical Psychopharmacology·J J RateyJ Bemporad
May 1, 1988·American Journal of Medical Genetics·R J HagermanM D Wittenberger
May 1, 1987·The British Journal of Psychiatry : the Journal of Mental Science·M CraftP M North
Sep 1, 1988·Journal of Autism and Developmental Disorders·M G Aman, A J White
Jan 1, 1986·American Journal of Medical Genetics·R J HagermanP J Hagerman
Sep 1, 1986·Journal of Autism and Developmental Disorders·M G AmanC J Teehan
Jan 1, 1974·The British Journal of Psychiatry : the Journal of Mental Science·G J NaylorA H Reid
May 1, 1968·The American Journal of Psychiatry·H W Burk, F J Menolascino
Jan 1, 1984·Progress in Neuro-psychopharmacology & Biological Psychiatry·S P TyrerD A Stephens
Oct 1, 1980·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R ElieJ M Albert
Oct 1, 1994·Journal of the American Academy of Child and Adolescent Psychiatry·B L HandenH Feldman
Feb 1, 1994·Journal of the American Academy of Child and Adolescent Psychiatry·R W RickettsJ C Cooke
Apr 1, 1994·Annals of Neurology·A K PercyS Waring
Jun 1, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·D F ConnorK E Fletcher
Jun 1, 1997·Journal of Intellectual Disability Research : JIDR·G MasiP Pfanner
Apr 6, 1999·Journal of Child Neurology·C EllawayJ Christodoulou
Jul 16, 1999·Journal of the American Academy of Child and Adolescent Psychiatry·B L HandenP J Murray
Feb 24, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·L L GreenhillT Wigal
May 1, 2001·Archives of Pediatrics & Adolescent Medicine·N J LobaughG Koren
Apr 20, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·W M VerhoevenS Tuinier
Mar 29, 2002·International Journal of Geriatric Psychiatry·Vee P PrasherUNKNOWN Down syndrome Ageing Study Group
Aug 3, 2002·The American Journal of Psychiatry·Michael G AmanUNKNOWN Risperidone Disruptive Behavior Study Group
Aug 21, 2002·American Journal of Mental Retardation : AJMR·John E KalachnikStuart R Harder
Sep 10, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Richard SnyderUNKNOWN Risperidone Conduct Study Group
Jan 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Deborah A PearsonLynne A Cleveland

❮ Previous
Next ❯

Citations

Nov 12, 2016·Frontiers in Public Health·Anton Rodney Miller, Peter Rosenbaum
Mar 30, 2018·Journal of Clinical Psychopharmacology·Sara LambrechtsAnnick Vogels
Jun 28, 2018·Journal of Applied Research in Intellectual Disabilities : JARID·Annabel FolchRafael Martínez-Leal
Nov 16, 2019·International Journal of Clinical Pharmacy·Anne Gerd GranasCecilie Johannessen Landmark
Apr 6, 2019·Nature Biomedical Engineering·Yamin LiQiaobing Xu
Aug 21, 2018·Irish Journal of Psychological Medicine·Bhathika Perera
Jan 27, 2019·Paediatrics & Child Health·Brenda Clark, Stacey A Bélanger
Aug 7, 2020·Journal of Population Therapeutics and Clinical Pharmacology Journal De La Thérapeutique Des Populations Et De La Pharamcologie Clinique·Mansfield MelaChristine Loock
Nov 9, 2018·Harvard Review of Psychiatry·Aaron J HauptmanDiane Stafford
May 1, 2019·Brain Sciences·Marwa Zafarullah, Flora Tassone
Nov 17, 2020·Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery·Jaime M MooreRichard E Boles
Nov 24, 2020·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Kazunari YoshidaDaniel J Müller
Jul 31, 2021·Journal of Applied Behavior Analysis·Alison D Cox, Javier Virues-Ortega

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
sedation

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused by a partial deletion of chromosome 22. Symptoms include heart defects, poor immune system function, a cleft palate, complications related to low levels of calcium in the blood, and delayed development. Discover the latest research on this disease here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Related Papers

Journal of Child and Adolescent Psychiatric Nursing : Official Publication of the Association of Child and Adolescent Psychiatric Nurses, Inc
L Scahill, K Lynch
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
B Vitiello
© 2022 Meta ULC. All rights reserved